| Filed On | Filing |
|---|---|
| 03 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification of the appointment ... |
| 18 May 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
PRINCETON, NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today ann... |
| 12 Nov 2025 |
8-K: Other Events
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option |
| 06 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As Representative of the several Underwriters named on Schedule 1 attached hereto |
| 22 Sep 2025 |
8-K: Other Events
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema |
| 10 Sep 2025 |
8-K: Other Events
Effective September 10, 2025, the Company’s common stock began trading on the OTCQB Market of the OTC Market Group under the symbol “PTNT”, reflecting the expiration of the twenty trading day period under the symbol “PTNTD” following the... |
| 18 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases |
| 08 Aug 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Palatin Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify: |
| 29 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On July 25, 2025, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) an amendment to the Company’s Re... |
| 09 Jul 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 7, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that a Listing Qualifications Panel (the “Panel”) of the Exchange’s Committee fo... |
| 13 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ... |
| 08 May 2025 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of May 7, 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 10 Apr 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
CRANBURY, NJ – April 10, 2025/PRNewswire/ – Palatin Technologies, Inc. (the “Company”) (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin... |
| 31 Mar 2025 |
8-K: Other Events
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. |
| 12 Feb 2025 |
8-K: Entry into a Material Definitive Agreement
Palatin Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: |
| 10 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2025 between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includin... |
| 16 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION U... |
| 14 Nov 2024 |
8-K: Results of Operations and Financial Condition
Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates |
| 07 Oct 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
CRANBURY, NJ – October 7, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor sys... |
| 01 Oct 2024 |
8-K: Results of Operations and Financial Condition
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) |
Loading...